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Abstract  
Background and Objective: Lenvatinib is an oral, multitargeted tyrosine kinase inhibitor (TKI) of 
vascular endothelial growth factor receptors (VEGFR1-VEGFR3), fibroblast growth factor receptors 
(FGFR1-FGFR4), platelet-derived growth factor receptor (PDGFR)α, rearranged during transfection 
(RET), and v-kit (KIT) signaling networks implicated in tumor angiogenesis.  
Method: Here we review the scientific literature about lenvatinib in the treatment of thyroid cancer. 
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Results: In vitro studies have shown antineoplastic activity of lenvatinib in differentiated thyroid 
cancer (DTC), mainly because of its antiangiogenetic effects, but a slight effect on thyroid cancer cell 
proliferation has been shown.  
In vivo phase II, and phase III studies in patients with  aggressive DTC not responsive to radioiodine, 
have shown that lenvatinib administration was associated with an amelioration in progression-free 
survival (PFS) with respect to placebo (median PFS 18.2 vs. 3.6 months). However overall survival 
was not significantly changed. Lenvatinib is also effective in patients resistant to sorafenib as salvage 
therapy. 
Adverse effects of any grade occur in more than 40% of lenvatinib-treated patients, mainly 
hypertension, diarrhea, asthenia or fatigue, nausea, decreased appetite, and decreased weight. 
Discontinuations of the therapy because of adverse effects occur in about 14% of patients. Moreover, 
deaths considered to be drug-related can occur.  
Conclusion: On the base of the above mentioned considerations, it is necessary to prove the 
effectiveness of lenvatinib in the context of associated moderate to severe toxicities requiring frequent 
dose reduction and delays, and for this reason many interesting patents have been recently applied. 
 
Running Title: Lenvatinib in aggressive thyroid cancer 
 
Keywords: anaplastic thyroid cancer; dedifferentiated thyroid cancer; follicular thyroid cancer; 
lenvatinib; papillary thyroid cancer; tyrosine kinase inhibitors. 
 
1. Introduction  
 
The most frequent endocrine malignancy is thyroid cancer (TC), with more than 60,000 cases each year 
in the US alone. Differentiated thyroid cancer (DTC) accounts for more than 90 % of all thyroid 
malignancies and its incidence has been rising continuously [1-4].  
Several risk factors are associated with DTC, such as the exposure to ionizing radiations in childhood 
or adolescence, that can cause especially papillary thyroid cancer (PTC) [5] as well as secondary 
radiations, or nuclear explosions or nuclear accidents [6, 7]. Exposure to low doses of radiations may 
cause the onset of thyroid nodules and cancer, too [8, 9]. Iodine deficiency is another risk factor, 
associated with a higher frequency of follicular thyroid cancer (FTC), while an increased frequency of 
PTC has been shown in iodine deficient areas, after the introduction of iodine prophylaxis [10, 11]. 
Hashimoto’s thyroiditis is associated with PTC and thyroid lymphoma [12-15]. PTCs and FTCs are 
treated with total thyroidectomy and aggressive PTCs and FTCs with successive radioactive iodine 
(RAI) remnant ablation with 131I, too [7, 16]. 
Basal and rTSH-stimulated thyroglobulin (Tg) determination, and neck ultrasonography are the key 
elements in the follow up of patients with PTC and FTC, previously been submitted to surgery [7, 17, 
18]. For more than 95 % of DTC patients, surgical treatment, RAI ablation, and thyroid-stimulating 
hormone (TSH) suppressive therapy reach an overall survival (OS) rate of about 98 % in 5 years. 
However, locoregional recurrence occurs in up to 10-20 % and distant metastases in approximately 5-
10 % at 10 years. Two-thirds of these patients will become RAI-refractory and for this reason they will 
never be cured with RAI therapy, with a 3-year OS rate lower than 50 %.  
Until recently, chemotherapy was the only treatment in patients with advanced DTC, but its humble 
effectiveness and significant toxicity needed for compelling advances in the therapy of advanced DTC.  
Over the last decade, substantial progress has been made in the management of RAI-refractory DTC. 
Thanks to the new knowledges in TC biology, novel targeted therapies for this disease have been 
developed, including the tyrosine kinase inhibitors (TKIs). In DTC, sorafenib was first approved as 
salvage treatment, and then in 2015, also lenvatinib was approved by the US Food and Drug 
Administration (FDA) for the treatment of RAI-refractory TC. 
Here we review the scientific literature about lenvatinib in the treatment of TC. 
 
2. Molecular pathways involved in the development of TC 
 
Different molecular pathways are involved in the pathogenesis of TC (Figure 1).  
About 40-50 % of gene alterations in PTCs are BRAF mutations, 30-40 % rearranged during 
transfection/PTC (RET/PTC), and 10 % RAS mutations, without overlaps. An increased prevalence of 
BRAF mutations (up to 70 %) has been reported in dedifferentiated papillary thyroid cancer (DePTCs) 
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[19, 20]. Approximately 35 % of gene alterations in FTCs are PAX8-/peroxisome proliferator-activated 
receptor (PPAR)γ rearrangement (PAX8-/PPARγ), 40-50 % RAS mutations [21, 22]. 
Mutations of the RET proto-oncogene are determinant in the familial forms and also in the sporadic 
forms of medullary thyroid carcinoma (MTC). 
Thanks to the knowledge of the molecular pathways at the basis of TC progression, it has been possible 
to develop new drugs able to block oncogenic kinases (V600EBRAF, RET/PTC) or signaling kinases 
[as vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptors 
(PDGFRs)] associated with cellular growth and proliferation [20]. 
 
3. TKIs 
 
TKIs, competing with the ATP-binding site of the catalytic domain of tyrosine kinases (TKs), are small 
compounds able to modulate TK-dependent oncogenic pathways [23], reducing autophosphorylation 
and TK activation, and in this way inhibiting the following activation of intracellular signaling 
pathways.  
TC initiation and progression involves multiple genetic and epigenetic alterations, of which RET/PTC 
gene rearrangements, RET or BRAF or RAS mutations, and VEGFR-2 mutations leading to the 
activation of the MAPK, the mTOR and PI3K-AKT signaling pathways are crucial [20]. TKIs can 
interact with one or several TKs, as a single TKI can target multiple TKs [24].  
As TKIs may induce clinical responses and stabilization of disease, they are currently used for the 
treatment of aggressive TC [DTC, MTC and anaplastic thyroid cancer (ATC)]. Vandetanib and 
cabozantinib have been approved for the treatment of MTC, and sorafenib and lenvatinib for DTC 
refractory to RAI [25-28]. These drugs protract median progression-free survival (PFS); however major 
side effects are frequent. New attempts are going on to find new more efficacious and safe compounds, 
and to personalize the therapy in each TC patient. 
 
4. Lenvatinib  
 
Lenvatinib is an oral, multitargeted TKI of VEGFR 1 through 3 (VEGFR1-VEGFR3), fibroblast 
growth factor receptors 1 through 4 (FGFR1-FGFR4), PDGFRα, RET, and v-kit Hardy-Zuckerman 4 
feline sarcoma viral oncogene homolog (KIT) signaling networks involved in tumor angiogenesis [29].  
It is used in form of the mesylate salt (CAS number 857890-39-2), for the treatment of dedifferentiated 
thyroid cancer (DeTC) that does not respond to RAI, and it is either locally recurrent or metastatic. 
 
4.1 Pharmacokinetics (PK) 
 
Lenvatinib is rapidly absorbed in the gut, the peak blood plasma concentrations is reached after 1-4 
hours (in fasting condition). Bioavailability is about 85 %. Lenvatinib circulates nearly completely (98–
99 %) bound to proteins (mainly albumin) [30]. 
It is metabolized by the CYP3A4 liver enzyme to desmethyl-lenvatinib (M2). Lenvatinib and M2 are 
oxidized by aldehyde oxidase (AO) to other substances called M2' and M3' [31]; these are the main 
metabolites in the feces. It is also metabolized to the N-oxide M3 by a CYP enzyme. Also non-
enzymatic metabolization occurs [30, 32]. 
The terminal half-life is 28 hours; about 2/3 are excreted via the feces, and 1/4 via the urine [30].  
 
5. In vitro studies  
 
A first study evaluated lenvatinib in RET gene fusion-driven preclinical models. Lenvatinib decreased 
auto-phosphorylation of KIF5B-RET, CCDC6-RET, and NcoA4-RET, inhibited the growth of CCDC6-
RET human thyroid and lung cancer cell lines, and suppressed tumorigenicity of RET gene fusion-
transformed NIH3T3 cells [33]. A second study evaluated the antitumor activity of lenvatinib against 
human TC xenograft models in nude mice. Orally administered lenvatinib showed antitumor activity in 
xenograft models of 5 DTC, 5 ATC, and 1 MTC xenograft models. Lenvatinib also showed 
antiangiogenetic activity in 5 DTC and 5 ATC xenografts, while the antiproliferative activity was 
shown in vitro only in 2 of 11 TC cell lines (i.e.,  RO82-W-1 and TT cells). Lenvatinib was also able to 
inhibit the RET phosphorylation in TT cells with the activated mutation C634W [34]. Most of the 
cancers have intrinsic or evasive resistance to VEGF inhibitors (by multiple mechanisms). Serum 
angiopoietin-2 (Ang2), and Tie2 [its receptor, that identifies a highly pro-angiogenic subset of 
macrophages, called “Tie2-expressing macrophages” (TEM)], have been shown to be potential 
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biomarkers of VEGF inhibitor response in different cancers. Ang2-Tie2 have critical roles in pericyte-
mediated vessel stabilization. A study evaluated a novel strategy to bypass the resistance by a 
combination of lenvatinib (VEGFR, FGFR, and RET inhibitor) and golvatinib (E7050, c-Met, Tie2, 
and EphB4 inhibitor). Golvatinib, in combination with lenvatinib, inhibited the stabilization of 
pericytes and TEM differentiation, as shown by in vitro studies. In TC models, golvatinib plus 
lenvatinib inhibited pericyte development and TEM infiltration, resulting in perfusion disorder and 
apoptosis. These preclinical studies suggested the combination of multi-targeting TKIs can sensitize 
cancer to VEGF inhibitors [35].  
 
6. In vivo studies 
 
6.1. Phase I studies, and pharmacokinetic 
In order to evaluate the biological and clinical activity of lenvatinib, and its safety, 77 patients were 
subdivided in 3 cohorts and treated per os twice daily in 28-day cycles: 18 with intermittent twice-daily 
dosing of 0.1-3.2 mg, 33 with twice-daily dosing of 3.2-12 mg, and 26 with twice-daily dosing of 10 
mg (expanded melanoma cohort). The maximum tolerated dose was 10 mg per os twice daily. 
Hypertension (43 %), proteinuria (39 %), fatigue (42 %), and nausea (25 %) were drug-related 
toxicities. Partial response (PR) was obtained in 15.6 % of patients (melanoma, 5/29 patients; thyroid, 
3/6; pancreatic, 1/2; lung, 1; renal, 1; endometrial, 1/4; and ovarian, 1/5), and stable disease (SD) in 
24.7 % [objective response rate (ORR) was 40.3 %]. In multivariate analyses, longer PFS was linked to 
increased baseline systolic blood pressure and decreased angiopoietin-1 ratio (after 2 hours) in patients 
with melanoma. 
This study concluded that the toxicity profile, PKs, and antitumor activity of lenvatinib were promising 
[36].  
Another phase I study enrolled Japanese patients with solid tumors in 2 cohorts, treating them with 20 
or 24 mg of lenvatinib orally on a once-daily continuous schedule (on a 28-day cycle, according to a 
conventional 3+3 dose escalation scheme). 
Nine patients received lenvatinib (20 mg in 3 subjects and 24 mg in 6 subjects). The most common 
adverse events (AEs) were thrombocytopenia, increased circulating TSH, and hypertension (89 %), and 
then leukopenia, headache, and proteinuria (78 %). PR was shown in 1 patient, and SD was maintained 
for more than 6 months by 3 patients. This study showed that Japanese patients with solid tumors 
tolerated the once-daily continuous dose of 24 mg of lenvatinib and it had promising antitumor activity 
[37]. 
A population PK analysis used pooled data from 15 clinical studies, including 8 phase I studies in 
healthy subjects, 4 phase I studies in patients with solid tumours, 2 phase II studies in patients with TC 
and 1 phase III study in patients with RAI-refractory DTC (RR-DTC). Data were collected from 779 
subjects treated with 3.2-32 mg oral lenvatinib in tablets or capsules, mainly once daily. The population 
mean value for lenvatinib apparent clearance (CL/F) was 6.56 l h(-1), and was independent of dose and 
time. The relative bioavailability of lenvatinib in capsule form was 90 % vs. tablets [percent coefficient 
of variation (% CV) 30.2]. Dose, pH-elevating agents, alanine aminotransferase, aspartate 
aminotransferase or bilirubin levels, or renal function, age, sex, race do not affect lenvatinib PK. The 
significant effects of several covariates on lenvatinib PK variability were small, and not clinically 
relevant [32]. 
 
6.2. Phase II studies 
A phase II trial enrolled 58 patients with advanced RR-DTC with a disease progression during the 
earlier 12 months, and administered them with lenvatinib (24 mg once daily) in 28-day cycles (till 
reaching disease progression, toxicity, withdrawal, or death); circulating levels of 51 cytokines and 
angiogenic factors were measured. The primary endpoint was the ORR; secondary endpoints included 
PFS and safety.  
After 14 months of follow-up, patients had an ORR of 50 %, and only PRs were reported. Median time 
to response (TTR) was 3.6 months, median response duration 12.7 months, and median PFS 12.6 
months. The ORR for the 17 patients who received previously VEGF therapy was 59 %. Lower 
baseline levels of angiopoietin-2 were associated with the tumor response and longer PFS. Grade 3 and 
4 treatment-emergent AEs [weight loss (12 %), hypertension (10 %), proteinuria (10 %), and diarrhea 
(10 %)] occurred in 72 % of patients. 
The comforting response rates, median TTR, and PFS in patients treated with lenvatinib led to the need 
of further investigations in a phase III trial [38].  
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A phase II trial was conducted in 59 patients with unresectable progressive MTC, who had been treated 
in the 12 previous months with lenvatinib (24 mg daily, on a 28-day cycle), until disease progression, 
toxicity, withdrawal, or death.  
Lenvatinib ORR was 36 %; all PRs. ORR was similar between patients with (35 %) or without (36 %) 
previous anti-VEGFR treatment. Disease control rate (DCR) was 80 %; 44 % had SD. Among 
responders, median TTR was 3.5 months. Median PFS was 9.0 months. AEs were diarrhea (14 %), 
hypertension (7 %), decreased appetite (7 %), fatigue, dysphagia and higher alanine aminotransferase 
levels (5 % each). The status of RET was not correlated with the obtained results. Low baseline levels 
of angiopoietin-2, HGF, and IL-8 were associated with tumor reduction and longer PFS.  
This study suggested that lenvatinib is effective in patients with documented progressive MTC [39].  
 
6.3. Phase III studies 
 
In a phase III, randomized, double-blind, multicenter study involving patients with progressive TC 
(refractory to iodine-131), 261 patients were administered with lenvatinib (24 mg daily in a 28-day 
cycle) and 131 received placebo. DTC patients in the placebo group could receive open-label 
lenvatinib, at the time of disease progression. The primary endpoint was PFS, and secondary endpoints 
were response rate, OS, and safety. 
The median PFS was significantly (P < 0.001) longer (18.3 months) in the lenvatinib group, than in the 
placebo group (and 3.6 months). The response rate was 64.8 %. In the lenvatinib group 4 complete 
responses and 165 PRs were observed, the response rate was 64.8 %, vs. 1.5 % in the placebo group (P 
< 0.001); OS was not reached in both groups. AEs of any grade (treatment related) occurred in > 40 % 
of patients in the lenvatinib group, and were: hypertension (67.8 % of patients), diarrhea (59.4 %), 
asthenia or fatigue (59.0 %), nausea (41.0 %), and decreased appetite (50.2 %) and decreased weight 
(46.4 %). Thirty-seven patients in the lenvatinib group (14.2 %) and 3 patients in the placebo group 
(2.3 %) discontinued the study drug owing to AEs. Moreover, during the treatment 6/20 deaths in the 
lenvatinib group, were considered to be drug-related. 
This study demonstrated that the therapy with lenvatinib in patients with iodine-131-refractory TC led 
to significant improvements in PFS and response rate. However, patients who received lenvatinib had 
more AEs, even severe [28]. 
Because of the results of this phase III study, lenvatinib received an FDA and European Medicines 
Agency (EMA) approval in February and March 2015 for the treatment of patients with locally 
recurrent or metastatic, progressive, RAI-refractory DTC [40].  
A subanalysis evaluated the efficacy and safety of lenvatinib in Japanese patients (30 treated with 
lenvatinib and 10 with placebo) who participated in Study of (E7080) Lenvatinib in Differentiated 
Cancer of the Thyroid (SELECT) and the results were assessed according to the SELECT population 
(lenvatinib, n = 261; placebo, n = 131).  
In Japanese patients, median PFS in those receiving lenvatinib was 16.5 months, and in the ones 
receiving placebo was 3.7 months, but the difference was not significant (P = 0.067). Overall response 
rates for lenvatinib were 63.3 % and for placebo 0 %. OS was not significantly different. The lenvatinib 
safety profile in Japanese patients was not significantly different from the one of the overall SELECT 
population, apart from higher incidences of hypertension (any grade: Japanese, 87 %; overall, 68 %; 
grade ≥ 3: Japanese, 80 %; overall, 42 %). Japanese patients had more dose reductions (Japanese, 90 
%; overall, 67.8 %), but fewer discontinuations due to AEs (Japanese, 3.3 %; overall, 14.2 %). This 
study suggested that in Japanese patients with RAI-refractory DTC, lenvatinib had similar clinical 
results as the overall SELECT population [41].  
A study evaluated tumor size changes linked to the therapy with lenvatinib, in the SELECT phase III, 
randomized, double-blind, multicenter study. Patients showing complete response or PR were 
considered responders to lenvatinib (n = 169), 76/92 nonresponders had at least one postbaseline tumor 
evaluation and were included in this analysis. Patients treated with lenvatinib (responders, -51.9 %; 
nonresponders, -20.2 %) had a median maximum percentage change in tumor size of -42.9 %. The 
reduction of tumor size was higher at the first evaluation (median, -24.7 % at 8 wk after 
randomization), then the rate of change diminished but was continuous (-1.3% per mo). In a 
multivariate model, percentage change in tumor size at the first evaluation was a slightly significant 
positive predictor for PFS. 
These findings suggest that tumor size changes associated with lenvatinib are characterized by two 
phases: a first rapid decline, and then a slower, continuous shrinkage [42].  
 
7. Anecdotal studies 
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The TKI sorafenib is a common first-line therapy for advanced DTC, even if responses do not last 
longer. A retrospective study determined the effectiveness of salvage therapy after first-line sorafenib 
failure, in patients with metastatic DTC (group 2). Patients who received first-line sorafenib only 
(group 1) were evaluated for comparison of OS. PFS, best response, and median OS were measured. 
Salvage therapy consisted of cabozantinib (n = 4), sunitinib (n = 4), vemurafenib (n = 3), lenvatinib (n 
= 3), and pazopanib (n = 3). 
Sixty-four patients with DTC were included: 35 in group 1 and 25 in group 2, and the groups were 
well-balanced. The 64 patients treated with first-line sorafenib had median OS of 37 months, and 
patients administered with salvage therapy had a significantly longer median than the ones with 
sorafenib alone (58 vs. 28 months, P = 0.013). Best responses with first-line sorafenib were PR in 2/15 
(13 %), SD in 10/15 (67 %), and progressive disease in 3/15 (20 %) patients. With salvage therapy, 
PRs were seen in 7/17 (41 %) and SD in 10/17 (59 %) patients. Median PFS was 7.4 months with first-
line sorafenib and 11.4 months with salvage therapy.  
This study concluded that targeted drugs, and lenvatinib, are efficacious salvage treatments after 
sorafenib failure, in spite of similar mechanisms of action, and should be offered to patients with DTC 
[43]. 
A case report described the rapid control of T3 thyrotoxicosis in patients with metastatic FTC treated 
with lenvatinib [44]. 
 
8. Limits and drug resistance  
Despite TKIs have a less toxicity respect to cytotoxic chemotherapy, they cause significant side effects 
(like fatigue, hypertension, cutaneous rash, mucositis, hand-and-foot syndrome, nausea, diarrhea, 
vomiting, and also thyroid dysfunction [45]), that can cause the discontinuation of the therapy with 
TKIs. 
Patients with DTC following a TKI-therapy in the clinical trials gave contrasting outcomes, probably 
caused by drug resistance arising from the activation of other mitogenic signals [46].  
TKIs act as an antiangiogenetic drugs, blocking tumor growth without removing tumor cells. 
Therefore, the combination of TKIs has been recently suggested [46], even if possible interaction 
between those are yet to be clarified [47].  
Testing the sensitivity of primary TC cells from each subject to different TKIs could ameliorate the 
efficacy of the treatments [48, 49].  
By human tumor cells, disease orientated in vitro drug screening has some predictive value for the 
activity of clinical responses [50, 51], and may be useful to prevent the administration of inefficacious 
chemotherapeutics to patients [52]. Chemosensitivity tests in vitro gave a prediction of in vivo efficacy 
in 60 % of cases [53], while there is an association of about 90 % between a negative chemosensitivity 
test in vitro and an ineffectiveness of the chemotherapy in vivo [51], permitting to avoid the 
administration of inactive drugs to patients.  
Primary TC cell cultures have been usually obtained from surgical biopsies performed for therapeutic 
or diagnostic procedures. Recently we demonstrated the possibility to overcome the problem of 
surgical procedures using fine-needle aspiration (FNA) cytology obtaining primary cell cultures from 
FNA samples of ATC (FNA-ANA); this paves the way to the use of FNA-ANA to test the sensitivity 
to different drugs in each patient. Thanks to this, unnecessary surgical procedures and the 
administration of inefficacious drugs could be avoided [48, 53-63]. 
 
9. Recent patents on lenvatinib in aggressive thyroid cancer  
 
Many patents have been applied in the last years, and we are reporting here some of them. 
Cell-targeted serine protease constructs (truncated serine protease polypeptides and fusion proteins) are 
provided, that can be used in methods for targeted cell killing, as for the treatment of proliferative 
diseases, like cancer. A truncated serine protease polypeptide refers to an engineered serine protease 
that is truncated such that the leader sequence, positioned N-terminally, has been removed or replaced 
with a heterologous sequence. Recombinant serine proteases, such as Granzyme B polypeptides, are 
provided with improved stability and cell toxicity. In order to increase its effectiveness, a serine 
protease therapeutic of the embodiments can be administered also in conjunction with a 
chemotherapeutic agent, as lenvatinib [64]. Another invention provides an anti-human Notch4 antibody 
or a Notch4 binding fragment with neutralizing activity against human Notch4. The Inventors obtained 
a mouse anti-human Notch4 antibody with a high neutralizing activity and binding affinity towards 
human Notch4 and determined the complementarity determining region (CDR) sequence of the mouse 
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anti-human Notch4 antibody. This led to the production of a humanized antibody with the variable 
region of heavy and light chains and the CDR sequence of the mouse anti-human Notch4 antibody 
[65]. The antitumor effect of the combined use of Antibody B [constituted by the heavy chain variable 
region of HK3 (human kappa light chain subgroup 3) and the light chain variable region of L3] and 
lenvatinib mesylate in a FTC238 human thyroid cancer cell line xenograft model has been shown. The 
change in relative tumor volume (RTV) (N=5, mean±standard error) of the control (non-treated) group, 
Antibody B administration group (twice-a-week tail vein administration), lenvatinib mesylate 
administration group (once-a-day oral administration), and Antibody B (twice-a-week tail vein 
administration)+lenvatinib mesylate (once-a-day oral administration) combination group were reported 
[65].  
A method for treating or ameliorating a solid tumor (as for example thyroid cancer) present in humans 
comprises administering intratumorally to the subject a unit dose of C. novyi colony forming units 
(CFUs) suspended in a pharmaceutically acceptable carrier or solution. The method includes a possible 
co-treatment protocol by the administration to the patient of a therapy selected from the group 
consisting of chemotherapy, radiation therapy, immunotherapy, and for example the C. novyi NT 
spores, simultaneously or at different times, as decided by the physician [66].  
Methods for treating solid tumors (as thyroid cancer) and hematological cancers by synergistic 
combinations of BET (bromodomain and extra-terminal) bromodomain inhibitor thieno-triazolo-1,4-
diazepine (JQ1) and/or its analogs with certain kinase inhibitors, anti-apoptotic agents and other 
specific anti-neoplastic agents have been shown. The synergistic effect of combining therapeutic agents 
leads to the use of lower dosages of one or more of the therapeutic agent(s) and/or less frequent 
administration to the patient, reducing the toxicity associated with the administration of the agent(s), 
and improving the efficacy [67].  
Another invention provides methods of treating or delaying progression of cancer using an anti-
angiogenesis agent (as a VEGF antagonist, like an anti-VEGF antibody) in combination with a PD-1 
axis binding antagonist (as anti-PD-L1 antibody) and an anti-OX40 antibody (like an antibody binding 
human OX40). A nonpeptide small molecule VEGF antagonist can include for example lenvatinib [68]. 
Moreover, a method for treating solid tumors (as thyroid cancer, even advanced or metastatic) in a 
patient includes (1) determining the presence or absence of a H-RAS mutation in the patient, and then 
(2) administering a therapeutically effective amount of a farnesyltransferase inhibitor (FTI) to the 
patient if a H-RAS mutation is detected. Some drugs can be used in combination with the FTI 
treatment, as lenvatinib [69].  
A method of preventing, treating or lessening the severity of a proliferative disease (as thyroid cancer) 
in a patient administered with a therapeutically effective amount of a bicyclic pyrazolone compound, 
used to inhibit or modulate the activity of receptor TKs, particularly Axl, c-Met, Mer, and Ron. Such 
compound comprises also a therapeutic agent selected from the group consisting of chemotherapeutic 
agents and anti-proliferative agents, like lenvatinib [70].  
Another invention is about methods for the treatment of cancer combining radiation, cerium oxide 
nanoparticles (CONPs; nanometer-sized crystals of cerium oxide of about 1-20 nm in longest 
dimension) and at least one chemotherapeutic agent, to enhance radiation-induced and chemotherapy-
induced cancer cell death and to reduce the toxicity associated with radiation therapy and 
chemotherapy. The cancer treated by the method of the present invention is a solid tumor, as thyroid 
cancer [71].  
A method for treating cancer (for example thyroid cancer) in a patient administering a combination 
therapy comprising an antagonist of a Programmed Death 1 protein (PD-1) and a multiple receptor TK 
(multi-RTK) inhibitor has been shown. The multi-RTK inhibitor my be represented by lenvatinib [72].  
 
Conclusion 
Lenvatinib is an oral, multitargeted TKI of VEGFR1-VEGFR3, FGFR1-FGFR4, PDGFRα, RET, and 
v-kit (KIT) signaling networks implicated in tumor angiogenesis.  
In vitro studies have shown antineoplastic activity of lenvatinib in DTC, mainly because of its 
antiangiogenetic effects, but a slight effect on TC cells proliferation has been shown.  
In vivo phase II, and phase III studies in patients with  aggressive DTC not responsive to RAI have 
shown that lenvatinib administration was linked to a significant PFS amelioration with respect to 
placebo (median PFS 18.2 vs. 3.6 months). However OS was not significantly changed. Lenvatinib is 
also effective in patients resistant to sorafenib as salvage therapy. 
AEs of any grade occur in more than 40 % of lenvatinib-treated patients, mainly hypertension, 
diarrhea, asthenia or fatigue, nausea, decreased appetite, and decreased weight. Discontinuations of the 
therapy because of AEs occur in about 14 % of patients. Moreover, deaths considered to be drug-
related can occur.  
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Many interesting patents have been recently applied. 
On the base of the above mentioned considerations, it is necessary to prove the benefit of lenvatinib in 
the context of associated moderate to severe toxicities requiring frequently dose reduction and delays 
[29, 73]. 
 
Current & Future Developments  
In vitro studies have shown the antineoplastic activity of lenvatinib in DTC, especially thanks to its 
antiangiogenetic effects.  
In vivo phase II, and phase III studies in patients with  aggressive DTC not responsive to radioiodine, 
have shown that lenvatinib administration was associated with an amelioration in PFS vs. placebo 
(median PFS 18.2 vs. 3.6 months), even if overall survival was not significantly changed.  
Adverse effects of any grade occur in more than 40 % of patients administered with lenvatinib, and 
discontinuations of the therapy because of adverse effects occur in about 14 % of patients. 
Furthermore, deaths considered to be drug-related can occur.  
Further studies are ongoing and many interesting patents have been recently applied.  
Future investigations are necessary to prove the effectiveness of lenvatinib in the context of associated 
moderate to severe toxicities requiring frequent dose reduction and delays. 
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Figure Legend 
 
Fig. 1. Molecular targets in the signaling pathways involved in aggressive thyroid cancer.  
 
 
 
 
 
